Profile data is unavailable for this security.
About the company
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
- Revenue in USD (TTM)9.67m
- Net income in USD-35.39m
- Incorporated1999
- Employees29.00
- LocationSCYNEXIS Inc1 Evertrust Plaza, 13Th FloorJERSEY CITY 07302-6548United StatesUSA
- Phone+1 (201) 884-5485
- Fax+1 (919) 544-8697
- Websitehttps://www.scynexis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fortress Biotech Inc | 82.62m | -49.54m | 43.80m | 186.00 | -- | 2.43 | -- | 0.5302 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Aadi Bioscience Inc | 23.82m | -65.44m | 46.03m | 70.00 | -- | 0.5842 | -- | 1.93 | -2.43 | -2.43 | 0.8829 | 3.20 | 0.1884 | 0.6393 | 4.96 | 267,606.80 | -51.76 | -50.25 | -60.12 | -56.15 | 87.18 | -- | -274.77 | -473.97 | 3.92 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 48.86m | 14.00 | -- | 2.04 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 50.91m | 5.00 | -- | 5.03 | -- | 123.86 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Earth Science Tech Inc | 20.30m | 1.98m | 55.41m | 32.00 | 28.06 | 17.50 | 25.84 | 2.73 | 0.0064 | 0.0064 | 0.0658 | 0.0103 | 5.40 | 36.44 | -- | 634,456.90 | 52.57 | -37.98 | 77.89 | -- | 69.40 | 63.87 | 9.74 | -15.48 | 1.24 | 3.57 | 0.0261 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 55.58m | 134.00 | 4.70 | 0.2224 | 1.70 | 0.2158 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 57.81m | 298.00 | -- | 1.32 | -- | 1.94 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 59.43m | 29.00 | -- | 0.9839 | -- | 6.15 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.76m | 25.00 | 20.57 | 5.51 | 19.92 | 5.42 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| CEL-SCI Corp | 0.00 | -29.10m | 68.87m | 43.00 | -- | 7.17 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 75.28m | 20.00 | -- | 7.66 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Journey Medical Corp | 77.68m | 843.00k | 75.40m | 58.00 | 51.00 | 9.07 | 18.39 | 0.9707 | -0.0131 | -0.0131 | 3.91 | 0.5642 | 1.15 | 2.36 | 5.71 | 1,339,328.00 | 1.25 | -- | 5.17 | -- | 66.79 | -- | 1.09 | -- | 1.08 | 2.00 | 0.6682 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to SCYNEXIS Inc's reporting currency: US Dollar USD
32.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 30 Jun 2024 | 4.21m | 11.13% |
| Kingdon Capital Management LLCas of 30 Jun 2024 | 2.24m | 5.91% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.68m | 4.44% |
| Avidity Partners Management LPas of 30 Jun 2024 | 1.45m | 3.83% |
| D.A. Davidson & Co. (Investment Management)as of 30 Jun 2024 | 549.22k | 1.45% |
| AMH Equity Ltd.as of 30 Jun 2024 | 545.00k | 1.44% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 540.68k | 1.43% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 416.08k | 1.10% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 372.75k | 0.99% |
| Geode Capital Management LLCas of 30 Jun 2024 | 362.45k | 0.96% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
